CR7589A - NEW ANTIBODIES DIRECTED AGAINST TISSULAR FACTORS AS ANTICOAGULANTS - Google Patents
NEW ANTIBODIES DIRECTED AGAINST TISSULAR FACTORS AS ANTICOAGULANTSInfo
- Publication number
- CR7589A CR7589A CR7589A CR7589A CR7589A CR 7589 A CR7589 A CR 7589A CR 7589 A CR7589 A CR 7589A CR 7589 A CR7589 A CR 7589A CR 7589 A CR7589 A CR 7589A
- Authority
- CR
- Costa Rica
- Prior art keywords
- tissular
- anticoagulants
- factors
- directed against
- antibodies directed
- Prior art date
Links
- 239000003146 anticoagulant agent Substances 0.000 title 1
- 229940127219 anticoagulant drug Drugs 0.000 title 1
- 102000002262 Thromboplastin Human genes 0.000 abstract 5
- 108010000499 Thromboplastin Proteins 0.000 abstract 5
- 208000004476 Acute Coronary Syndrome Diseases 0.000 abstract 1
- 206010051055 Deep vein thrombosis Diseases 0.000 abstract 1
- 108010054265 Factor VIIa Proteins 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 206010047249 Venous thrombosis Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 abstract 1
- 229940012414 factor viia Drugs 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 230000001732 thrombotic effect Effects 0.000 abstract 1
Landscapes
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Nuevos anticuerpos que se unen con mayor afinidad al complejo del factor VIIa/factor tisular (FVIIa/TF) que al factor tisular (TF) solamente, no compiten por la union a TF con FVII y FX e inhiben la activacion de FX. Los anticuerpos se unen en el sitio de la lesion y previenen el inicio de trombosis. Los anticuerpos se pueden usar para el tratamiento de diversas afecciones tromboticas incluyendo, a modo de ejemplo, trombosis de venas profundas, coagulacion intravascular diseminada y sindrome coronario agudo.New antibodies that bind with greater affinity to the factor VIIa / tissue factor complex (FVIIa / TF) than to the tissue factor (TF) alone, do not compete for binding to TF with FVII and FX and inhibit the activation of FX. Antibodies bind at the site of injury and prevent the onset of thrombosis. Antibodies can be used for the treatment of various thrombotic conditions including, for example, deep vein thrombosis, disseminated intravascular coagulation and acute coronary syndrome.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CR7589A CR7589A (en) | 2004-11-24 | 2004-11-24 | NEW ANTIBODIES DIRECTED AGAINST TISSULAR FACTORS AS ANTICOAGULANTS |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CR7589A CR7589A (en) | 2004-11-24 | 2004-11-24 | NEW ANTIBODIES DIRECTED AGAINST TISSULAR FACTORS AS ANTICOAGULANTS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR7589A true CR7589A (en) | 2006-07-14 |
Family
ID=44839260
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR7589A CR7589A (en) | 2004-11-24 | 2004-11-24 | NEW ANTIBODIES DIRECTED AGAINST TISSULAR FACTORS AS ANTICOAGULANTS |
Country Status (1)
| Country | Link |
|---|---|
| CR (1) | CR7589A (en) |
-
2004
- 2004-11-24 CR CR7589A patent/CR7589A/en not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP045467A (en) | NEW ANTIBODIES DIRECTED AGAINST TISSULAR FACTORS AS ANTICOAGULANTS | |
| BR0308928A (en) | Use of botulinum toxin for the treatment of cardiovascular disease, as well as composition for use in a cardiovascular procedure. | |
| AR109605A2 (en) | METHOD FOR TREATING PERIPHERAL VASCULAR DISEASES, COMPOSITION AND USE | |
| WO2010056765A3 (en) | Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents | |
| CR11486A (en) | TREATMENT OF UTERINE CANCER AND OVARIO CANCER WITH A PARP INHIBITOR ONLY OR IN COMBINATION WITH ANTI-TUMOR AGENTS | |
| BRPI0419206A (en) | absorbent article | |
| DOP2009000283A (en) | SIRTUINA MODULATING COMPOUNDS | |
| BR112012011042A2 (en) | ablation catheter. | |
| BRPI0516764A (en) | hemostat | |
| ECSP11011349A (en) | USE OF SYNTHETIC AND BIOLOGICAL FUNGICIDES IN COMBINATION TO CONTROL HARMFUL FUNGES | |
| ECSP11011490A (en) | USE OF SYNTHETIC AND BIOLOGICAL FUNGICIDES IN COMBINATION TO CONTROL HARMFUL FUNGES | |
| ATE442101T1 (en) | DEVICE AND KIT FOR TREATING DISORDERS OF THE CARDIAC RHYTHM REGULATION SYSTEM | |
| MX2019004573A (en) | METHODS TO AVOID CARDIOVASCULAR EVENTS BY REDUCING PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9). | |
| CY1110889T1 (en) | C-ARYLIC GLUCOSYSTEMS SGLT2 INSPECTIONS AND METHOD FOR PRODUCTION | |
| DE602007004643D1 (en) | DEVICE FOR IMPROVING THE HEARTLAPPING FUNCTION | |
| DE602007009408D1 (en) | VERSIONS OF BALLOON SEAMS | |
| WO2009042962A3 (en) | Antidotes for factor xa inhibitors and methods of using the same | |
| WO2009017863A3 (en) | Tissue non-specific alkaline phosphatase inhibitors and uses thereof for treating vascular calcification | |
| ATE451077T1 (en) | ARTIFICIAL BLOOD VESSEL | |
| DE602006021290D1 (en) | MODULATOR OF COAGULATION CASCADES AND FIBRINOLYTIC CASCADES | |
| ATE514815T1 (en) | FIBER STRUCTURES WITH ADDED LOW SURFACE ENERGY | |
| WO2006114105A3 (en) | Use of modified factor vii for treating bleeding | |
| PH12017502145A1 (en) | Composition and uses thereof | |
| CR7589A (en) | NEW ANTIBODIES DIRECTED AGAINST TISSULAR FACTORS AS ANTICOAGULANTS | |
| BRPI0607280A2 (en) | method of treatment or prevention of adhesive capsulitis in a patient in need of this treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal (granting procedure) |